Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02142803 · OUTCOME

Markers Associated With Dysregulated Cell Signaling

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · Source last updated 2026-08-28

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Baseline

What was measured

The biomarkers predicting response to mechanistic target of rapamycin (mTOR) inhibitor activity will be resulted by dose level and response status.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
The biomarkers predicting response to mechanistic target of rapamycin (mTOR) inhibitor activity will be resulted by dose level and response status.
reporting Status
NOT_POSTED
time Frame
Baseline
title
Markers Associated With Dysregulated Cell Signaling
type
OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice